EP0937056A1 - A process for the preparation of (-)-3,4-trans-diarylchromans - Google Patents

A process for the preparation of (-)-3,4-trans-diarylchromans

Info

Publication number
EP0937056A1
EP0937056A1 EP97909213A EP97909213A EP0937056A1 EP 0937056 A1 EP0937056 A1 EP 0937056A1 EP 97909213 A EP97909213 A EP 97909213A EP 97909213 A EP97909213 A EP 97909213A EP 0937056 A1 EP0937056 A1 EP 0937056A1
Authority
EP
European Patent Office
Prior art keywords
process according
cis
alkyl
salt
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97909213A
Other languages
German (de)
French (fr)
Inventor
Svend Treppendahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP0937056A1 publication Critical patent/EP0937056A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring

Definitions

  • the present invention relates to a novel and advantageous process for the preparation of (-)- 3,4-trans-diarylchromans of the following formula I:
  • R 1 , R 4 and R 5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C 1-6 alkyl, C ⁇ alkoxy or -0-(CH 2 ) n -NR 6 R 7 wherein n is an integer in the range of 1 to 6 and R 6 and R 7 independently are C ⁇ alkyl or R 6 and R 7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) which het- erocyclic group is optionally substituted with C h alky!; and R 2 and R 3 are individually hydrogen or C 1-6 alkyl; and salts thereof.
  • the present invention provides a process which comprises reacting a (+,-)-3,4-cis- diarylchroman with a chiral acid, e.g. (-)-di-p-toluoyltartaric acid, in an inert organic solvent to obtain the chiral acid salt, e.g. (-)-di-p-toluoyltartaric acid salt, of the (-)-3,4-cis enantiomer in crystalline form, subjecting the crystalline salt to hydrolysis and rearranging the (-)-3,4-cis enantiomer to the (-)-3,4-trans enantiomer with a strong base in an inert aprotic solvent.
  • a chiral acid e.g. (-)-di-p-toluoyltartaric acid
  • the present invention also relates to novel intermediates of formula III
  • R ⁇ R 2 , R 3 ,R 4 and R 5 are as defined above; or a salt thereof, useful in the preparation of the compounds of formula I.
  • U.S. Pat. No. 5,280,040 discloses a class of 3,4-diarylchromans and their salts useful in the treatment of bone loss due to osteoporosis or other conditions. Furthermore, PCT/DK96/00014 discloses that these compounds are useful in the treatment of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia, or hypercholesterolaemia or arteriosclerosis or for anticoaguiative treatment.
  • PCT/DK96/00015 discloses that these compounds are useful in the treatment of gynaecological disorders, such as endometriosis, dysfunctional bleedings, endometrial cancer, polycystic ovarian syndrome and anovulatoric bleeding and for the induction of endometrial thinning.
  • the compounds are also known to have useful effects on gynaecomastia, obesity, vasodilation (respectively from PCT/DK96/00012, PCT/DK96/00011 , and PCT/DK96/00013) and furthermore on e.g. Alzheimers disease (PCT/DK96/00010).
  • Example 1 of U.S. Pat. No. 4,447,622 describes the preparation of the (-)-3,4-trans enantiomer, shown by the following formula :
  • One object of the present invention is therefore to provide a new and improved process for the preparation of (-)-3,4-trans enantiomers of compounds of formula I which process is adaptable to large scale manufacture, provide good yields and high purity and reduce the cost of manufacture.
  • Another object of the present invention is to provide a new intermediate of formula III, which is useful in the preparation of compounds of formula I.
  • R 1 , R 4 and R 5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C 1- ⁇ alkyl, C,. 6 alkoxy or -0-(CH 2 ) n -NR 6 R 7 wherein n is an integer in the range of 1 to 6 and R 6 and R 7 independently are C ⁇ alkyl or R 6 and R 7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) which heterocyclic group is optionally substituted with C,. ⁇ alkyl; and R 2 and R 3 are individually hydrogen or C 1- ⁇ alkyl; or a salt thereof, comprises treating a cis-racemate of a compound of formula II
  • R 1 , R 2 , R 3 ,R 4 and R 5 are as defined above or a salt thereof with a chiral acid in an inert organic solvent, crystallizing the chiral acid salt of the (-)-3,4-cis enantiomer, hydrolyz- ing the optically active acid salt and rearranging the resulting (-)-3,4-cis enantiomer to the corresponding (-)-3,4-trans enantiomer of above formula I by treatment with a strong base in an aprotic solvent and optionally forming a salt thereof .
  • R 1 , R 4 and R 5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C ⁇ alkyl, C ⁇ alkoxy or -0-(CH 2 ) n -NR 6 R 7 wherein n is an integer in the range of 1 to 6 and R 6 and R 7 independently are C ⁇ alkyl or R 6 and R 7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) which heterocyclic group is optionally substituted with C ⁇ alkyl; and R 2 and R 3 are individually hydrogen or C ⁇ alkyl; or a salt thereof, comprises treating a cis-racemate of a compound of formula II
  • R ⁇ R 2 , R 3 ,R 4 and R 5 are as defined above or a salt thereof with (-)-di-p- toluoyltartaric acid in an inert organic solvent, crystallizing the (-)-di-p-toluoyltartaric acid salt of the (-)-3,4-cis enantiomer of formula III
  • R ⁇ R 2 , R 3 ,R 4 and R 5 are as defined above, hydrolyzing the optically active acid salt and rearranging the resulting (-)-3,4-cis enantiomer to the corresponding (-)-3,4-trans enantiomer of above formula I by treatment with a strong base in an aprotic solvent and optionally forming a salt thereof .
  • R 1 , R 2 , R 3 ,R 4 and R 5 are as defined above; and salts thereof.
  • Intermediates of formula III are useful for preparing the compounds of formula I, and moreover, some of these compounds of formula III posess the same pharmaceutical activity as compounds of formula I.
  • a preferred embodiment of the compound of formula III is the (-)-di-p-toluoyltartahc acid salt having the formula
  • R 2 and R 3 preferably are the same and C,. 6 alkyl, especially methyl;
  • R 4 is preferably hydrogen; and
  • R 5 is preferably -0-(CH 2 ) n -NR 6 R 7 wherein n is 2 and R 6 and R 7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) and optionally substituted with C,. 6 alkyl.
  • R 1 is in the 7-position and is hydroxy or C ⁇ aikoxy, particularly methoxy; each of R 2 and R 3 is methyl, R 4 is hydrogen, and R 5 is in the 4-position and is 2-(pyrrolidin-1-yl)ethoxy.
  • a preferred embodiment of the intermediate of formula III is 3,4-cis-7-methoxy-2,2-dimethyl- 3-phenyl-4- ⁇ 4-[2-(pyrrolidin-1-yl)ethoxy]phenyl ⁇ chromane or a salt thereof.
  • the compound of formula III can be obtained directly in a purity of more than 99% ee (enantiomeric excess) without further crystallization and that a stereoselective rearrangement of the (-)-3,4-cis enantiomer to the corresponding (-)-3,4- trans enatiomer of formula I is possible without any loss of chiral purity.
  • R ⁇ R 2 , R 3 ,R 4 and R s are as defined above.
  • the cis-racemate of formula II is reacted with a chiral acid like e.g. tartaric acid, lactic acid, mandelic acid, dibenzoyl tartaric acid camphorsulphonic acid or (-)- di-p- toluoyltartaric acid in an inert organic solvent.
  • a chiral acid like e.g. tartaric acid, lactic acid, mandelic acid, dibenzoyl tartaric acid camphorsulphonic acid or (-)- di-p- toluoyltartaric acid in an inert organic solvent.
  • (-)-Di-p-toluoyltartaric acid is the preferred chiral acid.
  • the resulting optically active acid salt of the (-)-3,4-cis enantiomer of formula II crystallizes from the reaction mixture by cooling.
  • any such solvent which is not attacked by the conditions may be used for example a C, 6 -alkanol or mixtures thereof with water, tetrahydrofuran, acetone or acetonitril. It is preferred to use a C, 6 -alkanol as the organic solvent e.g. methanol, etha- nol or propanol.
  • the optically active salt of the (-)-3,4-cis enantiomer is firstly hydrolyzed to obtain the (-)-3,4-cis enantiomer which is then rearranged to the (-)-3,4- trans enantiomer by treatment with a strong base in an aprotic solvent.
  • the treatment with the strong base is normally carried out by heating the mixture, preferably at 80 - 110 °C.
  • hydrolyzing agent is normally used a weak base as e.g. aqueous ammonia, sodium carbonate, potassium carbonate or the like.
  • strong bases for the rearrangement may be used potassium hydroxide, sodium hydroxide, metal alkoxides, such as sodium methoxide, sodium ethoxide or potassium t-butoxide , sodium hydride, alkyllithiums such as n-butyllithium and sec-butyllithium; methal amides, such as sodium amide, magnesium diisopropylamide and lithium diisopropylamide or the like.
  • the preferred strong bases are potassium hydroxide and potassium t-butoxide.
  • the most preferred strong base is potassium t-butoxide.
  • the preferred aprotic solvents are dimethylsulfoxide, dimethylformamide, N- methylpyrrolidone (NMP) and toluene or combinations thereof.
  • NMP N- methylpyrrolidone
  • organic acid can be used e.g. formic acid, fumaric acid, methanesulfonic acid or the like.
  • Formic acid is preferred.
  • Preferred compounds prepared by the process according to the invention include those in which R 1 is hydroxy or C ⁇ alkoxy, especially methoxy.
  • R 2 and R 3 preferably are the same and C 1-6 alkyl, especially methyl;
  • R 4 is preferably hydrogen;
  • R s is preferably - 0-(CH 2 ) n -NR 6 R 7 wherein n is 2 and R 6 and R 7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) and optionally substituted with C h alky!.
  • R 1 is in the 7- position and is hydroxy or C ⁇ alkoxy, particularly methoxy; each of R 2 and R 3 is methyl, R 4 is hydrogen, and R 5 is in the 4-position and is 2-(pyrrolidin-1-yl)ethoxy.
  • a preferred embodiment of the invention provides a process for the preparation of ( - ) - 3R.4R- trans - 7-methoxy-2,2-dimethyl-3-phenyl-4- ⁇ 4-[2-(pyrrolidin-1- yl)ethoxy]phenyl ⁇ chromane, herein referred to as levormeloxifene, or a salt, thereof prepared from 3,4-cis-7-methoxy-2,2-dimethyl-3-phenyl-4- ⁇ 4-[2-(pyrrolidin-1-yl)ethoxy]phenyl ⁇ chromane or a salt thereof, as shown in the following scheme 2.
  • the ( - ) -3R,4R- trans - 7-methoxy-2,2-dimethyl-3- phenyl-4- ⁇ 4-[2-(pyrrolidin-1-yl)ethoxy]phenyl ⁇ chromane is isolated as the hydrogen fumarate salt.
  • the preferred solvent for the reaction with (-)-di-p-toluoyltartaric acid is methanol.
  • the invention provides a process for the preparation of (- )-3,4-trans-2,2-dimethyl-3-phenyl-4- ⁇ 4-[2-(pyrrolidin-1-yl)ethoxy ⁇ phenyl-7-hydroxychroman.
  • C.,. 6 alkanol includes methanol, ethanol, propanol, isopropanol, butanol, and the like.
  • C 1 . 6 alkyl includes straight and branched chain alkyl radicals containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert- butyl, n-amyl, sec-amyl, n-hexyl, 2-ethylbutyl, 2,3-dimethylbutyl and the like.
  • C 1-6 alkoxy includes straight and branched chain alkoxy radicals containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-amyloxy, sec-amyloxy, n-hexyloxy, 2-ethylbutoxy, 2,3-dimethylbutoxy and the like.
  • Halogen includes chloro, fluoro, bromo and iodo.
  • heteroatom(s) preferably are selected among N, O, or S such as e.g., piperidine, pyrrolidine, N-methyipiperazine or morpholine.
  • 3,4-diarylchromans of formula I may be prepared in the form of salts thereof e.g. pharmaceutically acceptable salts, especially acid-addition salts, including salts of organic acids and mineral acids.
  • pharmaceutically acceptable salts especially acid-addition salts, including salts of organic acids and mineral acids.
  • salts include salts of organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid and the like.
  • Suitable inorganic acid-addition salts include salts of hydrochloric, hy- drobromic, sulphuric and phosphoric acids and the like.
  • the acid addition salts may be ob- tained from the free base in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent e.g. by crystallisation.
  • the starting compound for the process, the cis-racemate of formula II may be prepared according to known methods, such as those disclosed in U.S. Pat. No. 3,340,276 to Carney et al., U.S. Pat. No. 3,822,287 to Bolger, and Ray et al.. J Med Chem 19 (1976), 276 - 279, the contents of which are incorporated herein by reference.
  • the compound of formula II might also be prepared by hydrogenation of the corresponding chromene using e.g. palladium on carbon following the scheme:
  • the oxidation may be carried out with a quinone in an inert solvent as e.g. xylene, 1- butanol, propyien glycol or ethylen glycol and in presence of an organic acid as e.g. acetic acid or inorganic acid as e.g. hydrochloric acid and a supplementary oxidizing agent as e.g. sulfur. It is preferred to use chloranil as oxidizing agent, hydrochloride acid as inorganic acids and ethylen glycol as solvent.
  • the optically active acid is preferably (-)-di-p-toluoyltartaric acid.
  • This acid is much cheaper than the (+)-di-p-toluoyltartaric acid used in the process described in U.S. Pat. No. 4,447,662. This also makes the process of the invention more economic over the known process.
  • the aqueous phase was separated and extracted with another portion of toluene (20 ml).
  • the combined organic phases was washed with water (2x50 ml) and evaporated to an oil.
  • the oil was dissolved in methanol (100 ml) and crystallized by adding water (200 ml).
  • the product was filtered off and dried. Yield 28 g (98 %), m.p. 118 - 119 °C.
  • the identity of the product was verified by 1 H-NMR and elemental analysis.
  • Chiral HPLC The enantiomeric purity was determined by Chiral HPLC to be better than 99 %.
  • the oil was dissolved in ethanol (135 ml) at 40 °C and mixed with a solution of fumaric acid (9.1 g) in ethanol (265 ml) at 40 - 60 °C. The mixture was stirred for 2 hours at ambient temperature and then for 1 hour at 0 °C. The crystals were filtered off and dried.
  • Chiral HPLC By Chiral HPLC the enantiomeric purity was determined to be better than 99.5 % and the identity to be hydrogen fumarate salt of levormeloxifene, i.e. the minus enantiomer of the racemic compound Centchroman.
  • the product was purified further by a crystallisation of the base from ethanol - water.
  • the product (670 g) was dissolved in a mixture of ethanol ( 2.66 I ) and water ( 0.7 I ) by heating to 60 °C.
  • a solution of sodium hydroxide (121 ml , 36 %) was added.
  • the solution was seeded while the mixture was 50 - 60 °C.
  • the mixture was cooled down to ca. 10 °C and the product filtered off and washed with 75 % ethanol (3 times 300 ml) and dried. Yield 520 g, 79 %.
  • the oil was dissolved in ethanol (16 ml) at 40 °C and mixed with a suspension of fumaric acid (4.2 g) in ethanol (31 ml) at 60 °C. The mixture was stirred. Additional ethanol (47 ml) was added and the mixture was refluxed for 3 hours. The mixture was stirred at ambient temperature overnight. The crystals were filtered off and dried.

Abstract

The present invention relates to a process for the preparation of (-)-3,4-trans-diarylchromans of formula (I), wherein R?1, R4 and R5¿ are individually hydrogen, hydroxy, halogen, trifluoromethyl, C¿1-6?alkyl, C1-6alkoxy or -O-(CH2)n-NR?6R7¿ wherein n is an integer in the range of 1 to 6 and R?6 and R7¿ independently are C¿1-6?alkyl or R?6 and R7¿ together with the N atom is a saturated or unsaturated 5- or 6-membered heterocyclic group containing one or two heteroatom(s) which heterocyclic group is optionally substituted with C¿1-6?alkyl; and R?2 and R3¿ are individually hydrogen or C¿1-6?alkyl; and salts thereof. The present invention provides a process which comprises reacting a (+,-)-3,4-cis-diarylchroman with a chiral acid, e.g. (-)-di-p-toluoyltartaric acid, in an inert organic solvent to obtain the chiral acid salt, e.g. (-)-di-p-toluoyltartaric acid salt, of the (-)-3,4-cis enantiomer in crystalline form, subjecting the crystalline salt to hydrolysis and rearranging the (-)-3,4-cis enantiomer to the (-)-3,4-trans enantiomer with a strong base in an inert aprotic solvent.

Description

A Process for the preparation of (-)-3,4-trans-diarylchromans
FIELD OF INVENTION
The present invention relates to a novel and advantageous process for the preparation of (-)- 3,4-trans-diarylchromans of the following formula I:
wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C1-6alkyl, C^alkoxy or -0-(CH2)n-NR6R7 wherein n is an integer in the range of 1 to 6 and R6 and R7 independently are C^alkyl or R6 and R7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) which het- erocyclic group is optionally substituted with Chalky!; and R2 and R3 are individually hydrogen or C1-6alkyl; and salts thereof.
The present invention provides a process which comprises reacting a (+,-)-3,4-cis- diarylchroman with a chiral acid, e.g. (-)-di-p-toluoyltartaric acid, in an inert organic solvent to obtain the chiral acid salt, e.g. (-)-di-p-toluoyltartaric acid salt, of the (-)-3,4-cis enantiomer in crystalline form, subjecting the crystalline salt to hydrolysis and rearranging the (-)-3,4-cis enantiomer to the (-)-3,4-trans enantiomer with a strong base in an inert aprotic solvent.
The present invention also relates to novel intermediates of formula III
wherein R\ R2 , R3 ,R4 and R5 are as defined above; or a salt thereof, useful in the preparation of the compounds of formula I.
BACKGROUND OF THE INVENTION
U.S. Pat. No. 5,280,040 discloses a class of 3,4-diarylchromans and their salts useful in the treatment of bone loss due to osteoporosis or other conditions. Furthermore, PCT/DK96/00014 discloses that these compounds are useful in the treatment of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia, or hypercholesterolaemia or arteriosclerosis or for anticoaguiative treatment. PCT/DK96/00015 discloses that these compounds are useful in the treatment of gynaecological disorders, such as endometriosis, dysfunctional bleedings, endometrial cancer, polycystic ovarian syndrome and anovulatoric bleeding and for the induction of endometrial thinning. The compounds are also known to have useful effects on gynaecomastia, obesity, vasodilation (respectively from PCT/DK96/00012, PCT/DK96/00011 , and PCT/DK96/00013) and furthermore on e.g. Alzheimers disease (PCT/DK96/00010).
A process for the preparation of ( +,- ) -3,4-trans diarylchromanes is described in U.S. Pat. No. 3,822,287 and by Suprabhat Ray et al. in J.Med.Chem.19,276 (1976). The ( +,- ) -3,4-trans- isomer is obtained by conversion of the ( +,- ) -3,4-cis-isomer by means of an organometallic base-catalyzed rearrangement as described in US Patent Specification No. 3,822,287.
The resolvation of ( +,- ) - 3,4-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1 - yl)ethoxy]phenyl}chromane in its optical antipodes is described in U.S. Pat. No. 4,447,622. According to this process the ( +,- )- 3,4- trans - 7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2- (pyrrolidin-1-yl)ethoxy]phenyl}chromane is reacted with di-p-toluoyl-l-tartaric acid monohy- drate in a protic solvent, the reaction mixture is subjected to fractional crystallization and the crystalline salt is subjected to alkaline hydrolysis to produce the desired enantiomer.
Example 1 of U.S. Pat. No. 4,447,622 describes the preparation of the (-)-3,4-trans enantiomer, shown by the following formula :
When using the process disclosed in U.S. Pat. No. 4,447,622 the desired (-)-3,4-trans enantiomer is only obtained with a low chiral purity, less than 80% ee (enantiomeric excess) after the first crystallization. In order to improve the chiral purity the enantiomer has to be crystal- lized several times.
One object of the present invention is therefore to provide a new and improved process for the preparation of (-)-3,4-trans enantiomers of compounds of formula I which process is adaptable to large scale manufacture, provide good yields and high purity and reduce the cost of manufacture.
Another object of the present invention is to provide a new intermediate of formula III, which is useful in the preparation of compounds of formula I.
DESCRIPTION OF THIS INVENTION.
The process of the invention for the preparation of a (-)-3,4-trans-compound of formula I
wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C1-βalkyl, C,.6alkoxy or -0-(CH2)n-NR6R7 wherein n is an integer in the range of 1 to 6 and R6 and R7 independently are C^alkyl or R6 and R7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) which heterocyclic group is optionally substituted with C,.βalkyl; and R2 and R3 are individually hydrogen or C1-βalkyl; or a salt thereof, comprises treating a cis-racemate of a compound of formula II
wherein R1, R2 , R3 ,R4 and R5 are as defined above or a salt thereof with a chiral acid in an inert organic solvent, crystallizing the chiral acid salt of the (-)-3,4-cis enantiomer, hydrolyz- ing the optically active acid salt and rearranging the resulting (-)-3,4-cis enantiomer to the corresponding (-)-3,4-trans enantiomer of above formula I by treatment with a strong base in an aprotic solvent and optionally forming a salt thereof .
In a preferred embodiment the process of the invention for the preparation of a (-)-3,4-trans- compound of formula I
wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C^alkyl, C^alkoxy or -0-(CH2)n-NR6R7 wherein n is an integer in the range of 1 to 6 and R6 and R7 independently are C^alkyl or R6 and R7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) which heterocyclic group is optionally substituted with C^alkyl; and R2 and R3 are individually hydrogen or C^alkyl; or a salt thereof, comprises treating a cis-racemate of a compound of formula II
R'
wherein R\ R2 , R3 ,R4 and R5 are as defined above or a salt thereof with (-)-di-p- toluoyltartaric acid in an inert organic solvent, crystallizing the (-)-di-p-toluoyltartaric acid salt of the (-)-3,4-cis enantiomer of formula III
wherein R\ R2 , R3 ,R4 and R5 are as defined above, hydrolyzing the optically active acid salt and rearranging the resulting (-)-3,4-cis enantiomer to the corresponding (-)-3,4-trans enantiomer of above formula I by treatment with a strong base in an aprotic solvent and optionally forming a salt thereof .
Furthermore, the invention relates to intermediate compounds of formula III
wherein R1, R2 , R3 ,R4 and R5 are as defined above; and salts thereof. Intermediates of formula III are useful for preparing the compounds of formula I, and moreover, some of these compounds of formula III posess the same pharmaceutical activity as compounds of formula I.
A preferred embodiment of the compound of formula III is the (-)-di-p-toluoyltartahc acid salt having the formula
Preferred Intermediates of formula III of the invention include those in which R1 is hydroxy or
C,.6alkoxy, especially methoxy. Furthermore, R2 and R3 preferably are the same and C,. 6alkyl, especially methyl; R4 is preferably hydrogen; and R5 is preferably -0-(CH2)n-NR6R7 wherein n is 2 and R6 and R7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) and optionally substituted with C,.6alkyl. Within particularly preferred embodiments, R1 is in the 7-position and is hydroxy or C^aikoxy, particularly methoxy; each of R2 and R3 is methyl, R4 is hydrogen, and R5 is in the 4-position and is 2-(pyrrolidin-1-yl)ethoxy.
A preferred embodiment of the intermediate of formula III is 3,4-cis-7-methoxy-2,2-dimethyl- 3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane or a salt thereof.
It has surprisingly been found that the compound of formula III can be obtained directly in a purity of more than 99% ee (enantiomeric excess) without further crystallization and that a stereoselective rearrangement of the (-)-3,4-cis enantiomer to the corresponding (-)-3,4- trans enatiomer of formula I is possible without any loss of chiral purity.
By the process disclosed in US Patent Specification No. 4,447,622 the (-)-3,4-trans enantiomer is only obtained in a chiral purity above 80% ee by crystallization several times.
Also the yield of (-)-3,4-trans enantiomer obtained by the process of the invention is much better than the yield obtained by the already known process. The process of the invention is shown in the following scheme 1 :
Scheme 1.
wherein R\ R2 , R3 ,R4 and Rs are as defined above.
In the first step the cis-racemate of formula II is reacted with a chiral acid like e.g. tartaric acid, lactic acid, mandelic acid, dibenzoyl tartaric acid camphorsulphonic acid or (-)- di-p- toluoyltartaric acid in an inert organic solvent. (-)-Di-p-toluoyltartaric acid is the preferred chiral acid. The resulting optically active acid salt of the (-)-3,4-cis enantiomer of formula II crystallizes from the reaction mixture by cooling.
As the inert organic solvent any such solvent which is not attacked by the conditions may be used for example a C, 6-alkanol or mixtures thereof with water, tetrahydrofuran, acetone or acetonitril. It is preferred to use a C, 6-alkanol as the organic solvent e.g. methanol, etha- nol or propanol.
In the second step of the procedure the optically active salt of the (-)-3,4-cis enantiomer is firstly hydrolyzed to obtain the (-)-3,4-cis enantiomer which is then rearranged to the (-)-3,4- trans enantiomer by treatment with a strong base in an aprotic solvent. The treatment with the strong base is normally carried out by heating the mixture, preferably at 80 - 110 °C.
It is not necessary to isolate the (-)-3,4-cis enantiomer before the rearrangement. The treat- ment with the strong base can be carried out directly in the organic phase resulting from the hydrolysis. The desired enantiomer may be isolated as a salt thereof.
As hydrolyzing agent is normally used a weak base as e.g. aqueous ammonia, sodium carbonate, potassium carbonate or the like.
As strong bases for the rearrangement may be used potassium hydroxide, sodium hydroxide, metal alkoxides, such as sodium methoxide, sodium ethoxide or potassium t-butoxide , sodium hydride, alkyllithiums such as n-butyllithium and sec-butyllithium; methal amides, such as sodium amide, magnesium diisopropylamide and lithium diisopropylamide or the like. The preferred strong bases are potassium hydroxide and potassium t-butoxide. The most preferred strong base is potassium t-butoxide.
The preferred aprotic solvents are dimethylsulfoxide, dimethylformamide, N- methylpyrrolidone (NMP) and toluene or combinations thereof. The combination NMP tolu- ene and toluene DMSO is the preferred.
It is preferred to replace part of the chiral acid, e.g. (-)-di-p-toluoyltartaric acid, with a weak organic acid such as formic acid or fumaric acid in order to obtain a more economical process and a better separation.
As organic acid can be used e.g. formic acid, fumaric acid, methanesulfonic acid or the like. Formic acid is preferred. Preferred compounds prepared by the process according to the invention include those in which R1 is hydroxy or C^alkoxy, especially methoxy. Furthermore, R2 and R3 preferably are the same and C1-6alkyl, especially methyl; R4 is preferably hydrogen; and Rs is preferably - 0-(CH2)n-NR6R7 wherein n is 2 and R6 and R7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) and optionally substituted with Chalky!. Within particularly preferred embodiments, R1 is in the 7- position and is hydroxy or C^alkoxy, particularly methoxy; each of R2 and R3 is methyl, R4 is hydrogen, and R5 is in the 4-position and is 2-(pyrrolidin-1-yl)ethoxy.
A preferred embodiment of the invention provides a process for the preparation of ( - ) - 3R.4R- trans - 7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1- yl)ethoxy]phenyl}chromane, herein referred to as levormeloxifene, or a salt, thereof prepared from 3,4-cis-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane or a salt thereof, as shown in the following scheme 2.
Scheme 2.
In sceme 1 and 2 above the compounds of formula III and formula (iii) are shown as the (-)- di-p-toluoyltartaric acid salt for the purpose of illustration only. However, the invention is by no means limited thereto, but is intended to comprise any chiral acid salt of the (-)-3,4-cis enantiomer.
In a particularly preferred embodiment the ( - ) -3R,4R- trans - 7-methoxy-2,2-dimethyl-3- phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane is isolated as the hydrogen fumarate salt. For the preparation of ( - ) -3R.4R- trans - 7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin- 1-yl)ethoxy]phenyl}chromane the preferred solvent for the reaction with (-)-di-p-toluoyltartaric acid is methanol.
In a further preferred embodiment the invention provides a process for the preparation of (- )-3,4-trans-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy}phenyl-7-hydroxychroman.
As used herein, the term "C.,.6alkanol" includes methanol, ethanol, propanol, isopropanol, butanol, and the like.
As used herein, the term " C1.6alkyl" includes straight and branched chain alkyl radicals containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert- butyl, n-amyl, sec-amyl, n-hexyl, 2-ethylbutyl, 2,3-dimethylbutyl and the like.
The term " C1-6alkoxy" includes straight and branched chain alkoxy radicals containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-amyloxy, sec-amyloxy, n-hexyloxy, 2-ethylbutoxy, 2,3-dimethylbutoxy and the like. "Halogen" includes chloro, fluoro, bromo and iodo. Herein, the term "5- or 6- membered heterocyclic group containing one or two hetero atom(s)" include groups wherein the heteroatom(s) preferably are selected among N, O, or S such as e.g., piperidine, pyrrolidine, N-methyipiperazine or morpholine.
Within the present invention, 3,4-diarylchromans of formula I may be prepared in the form of salts thereof e.g. pharmaceutically acceptable salts, especially acid-addition salts, including salts of organic acids and mineral acids. Examples of such salts include salts of organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid and the like. Suitable inorganic acid-addition salts include salts of hydrochloric, hy- drobromic, sulphuric and phosphoric acids and the like. The acid addition salts may be ob- tained from the free base in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent e.g. by crystallisation. The starting compound for the process, the cis-racemate of formula II may be prepared according to known methods, such as those disclosed in U.S. Pat. No. 3,340,276 to Carney et al., U.S. Pat. No. 3,822,287 to Bolger, and Ray et al.. J Med Chem 19 (1976), 276 - 279, the contents of which are incorporated herein by reference. The compound of formula II might also be prepared by hydrogenation of the corresponding chromene using e.g. palladium on carbon following the scheme:
In connection with the process of the invention it has been found that it is possible to oxidize the (+)-cis-enantiomer left over from the crystallization in the first step of the process of the invention to the corresponding chromene. This is an additional advantage of the process of the invention by further reducing the cost of manufacture and providing an overall higher yield. The oxidation may be carried out with a quinone in an inert solvent as e.g. xylene, 1- butanol, propyien glycol or ethylen glycol and in presence of an organic acid as e.g. acetic acid or inorganic acid as e.g. hydrochloric acid and a supplementary oxidizing agent as e.g. sulfur. It is preferred to use chloranil as oxidizing agent, hydrochloride acid as inorganic acids and ethylen glycol as solvent.
According to the invention the optically active acid is preferably (-)-di-p-toluoyltartaric acid. This acid is much cheaper than the (+)-di-p-toluoyltartaric acid used in the process described in U.S. Pat. No. 4,447,662. This also makes the process of the invention more economic over the known process.
The process of the invention is described in greater detail in the following non-limitative ex- amples. EXAMPLE 1
cis-7-Methoxy-2.2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane
7-Methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrroiidin-1 -yl)ethoxy]phenyl}-3-chromene (25 g) was dissolved in acetic acid (250 ml) at 60 °C. Palladium on carbon (2.5 g, 10 %, 50 % wet) was added and the mixture hydrogenated at 1 atmosphere hydrogen pressure at 60 °C for 24 hours. The catalyst was filtered off and the filtrate evaporated to en oil . The oil was dis- solved in toluene (100 ml) and washed with sodium hydroxide solution (4 M) until alkaline. The aqueous phase was separated and extracted with another portion of toluene (20 ml). The combined organic phases was washed with water (2x50 ml) and evaporated to an oil. The oil was dissolved in methanol (100 ml) and crystallized by adding water (200 ml). The product was filtered off and dried. Yield 28 g (98 %), m.p. 118 - 119 °C. The identity of the product was verified by 1 H-NMR and elemental analysis.
EXAMPLE 2.
(- cis-7-Methoxy-2.2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-vπethoxy]phenyl}chromane (-)- O.O'-ditoluoyltartrate
cis-7-Methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1 -yl)ethoxy]phenyl}chromane (109 g) was dissolved in methanol (2 I) at 50 °C. (-)-0,0'-ditoluoyltartaric acid (54,1 g) was added and then formic acid (6.8 ml). The solution was slowly cooled down to 32 °C and seeded. The product crystallized slowly overnight at ambient temperature. The mixture was cooled down to 0°C for 4 hours and filtered off and washed with methanol (230 ml). The enantiomeric purity was determined by Chiral HPLC to be better than 99 %. Chiral HPLC system: Column: Chiradex 5, 250x4 mm(Merck). Eluent: 30 % methanol/buffer (1 % triethylammonium acetate, pH = 4.1).
Yield 69 g (78 %), m.p. 138 -139 °C. The structure of the compound was verified by 1 H- NMR and elemental analysis. The composition of the salt is 4:3 i.e. four moles of base to three moles of ditoluoyl tartaric acid. Optical rotation of the free base, [ α ]p20 = - 51.3 °(c = 1 % in abs. ethanol).
EXAMPLE 3.
(-Mrans-7-Methoxy-2.2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl)chromane hydrogenfumarate
(-)-cis-7-Methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane (-)- O.O'-ditoluoyltartrate (66.3 g) was suspended in a mixture of toluene (330 ml), water (265 ml) and sodium carbonate (20.8 g). The mixture was stirred until all salts have dissolved. The aqueous phase was separated and extracted with another portion of toluene (65 ml). The combined organic phase was washed with water (3x130 ml). The organic phase was dried by removal of water in an azeotropic distillation. To the dry toluene solution was added dimethylsulfoxide (66 ml) and finely grinded potassium hydroxide (15.4 g). The mixture was heated to reflux while water was distilled from the mixture. The reflux was maintained for 6 hours. The reaction mixture was cooled down to room temperature, water ( 200 ml) was added and the mixture stirred until all the salt was dissolved. The aqueous phase was separated and extracted with another portion of toluene (135 ml). The organic phases were pooled washed with water (2x200 ml) and evaporated to an oil. The oil was dissolved in ethanol (135 ml) at 40 °C and mixed with a solution of fumaric acid (9.1 g) in ethanol (265 ml) at 40 - 60 °C. The mixture was stirred for 2 hours at ambient temperature and then for 1 hour at 0 °C. The crystals were filtered off and dried.
By Chiral HPLC the enantiomeric purity was determined to be better than 99.5 % and the identity to be hydrogen fumarate salt of levormeloxifene, i.e. the minus enantiomer of the racemic compound Centchroman. Chiral HPLC system: Column: Chiradex 5 , 250x4 mm(Merck). Eluent: 70 % methanol/buffer (0.25 % triethylammonium acetate, pH = 5.2). Yield 43 g (85 %), m.p. 220 °C with slight decomposition. The structure of the compound was verified by ^ H-NMR and elemental analysis.
EXAMPLE 4.
7-Methoxy-2.2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-3-chromene The filtrate from the crystallization of (-)-cιs-7-methoxy-2,2-dιmethyl-3-phenyl-4-{4-[2- (pyrrolιdιn-1-yl)ethoxy]phenyl}chromane (-)-0,0'-dιtoluoyltartrate was evaporated to an oil The oil was dissolved in a mixture of toluene (300 ml) water ( 300 ml) and sodium hydroxide (4M, 200 ml) The aqueous phase was separated and extracted with another portion of tolu- ene (100 ml) The combined toluene phase was washed with water and evaporated to an oil (73 g) which solidified on standing
A sample (1 g) of this solid was dissolved in xylene (20 ml, mixture of isomers) Acetic acid (1 ml), chloranil (0 5 g) and sulfur (0 5 g) was added and the mixture refluxed overnight Water (50 ml) and sodium hydroxide (4M, 20 ml) was added and then sodium dithionite ( 2 g) The mixture was stirred for 5 hours The aqueous phase was separated and the organic phase chromatographed through a short silica column with methanol as eluent The fractions containing the product was combined Concentrated hydrochloric acid ( 2 ml) was added and the solution was evaporated to dryness Yield 0 9 g (90 %), m p 219 °C, turns brown from 180 - 190 °C The identity of the product was verified by "Η-NMR and elemental analysis
EXAMPLE 5
7-Methoxy-2.2-dιmethyl-3-phenyl-4-{4-[2-(pyrrolιdιn-1-yπethoxy]phenyl}-3-chromene
A mixture of (+) - and (-) -levormeloxifene (670 g), the filtrates from resolution of racemic cιs-7-Methoxy-2,2-dιmethyl-3-phenyl-4-{4-[2-(pyrrolιdιn-1-yl)ethoxy]phenyl}chromane was dissolved in toluene (3 I) Cone hydrochloric acid (0 21 I) was added and the mixture dried by an azeotropic distillation The hydrochloπde crystallises, after seeding, from the toluene solution when dry The mixture was cooled down to 20 °C and the product filtered off and dried Yield 650 g, 90 %
The product (650 g) and chloranil (434 g) was dissolved in ethylene glycol (3,6 I) The solution was heated at 90 - 125 °C until completion For 3 hours at 125°C and 72 hours at 90 °C The mixture was cooled down to 20 - 30 °C and toluene (8 I) and sodium hydroxide ( 1 06 I, 36 %) was added The mixture was stirred for 10 minutes and the organic phase was separated off Cone hydrochloric acid (0 36 I) was added to the organic phase and a mixture of water-ethylene glycol-toluene was distilled from the solution until the distillation temperature reached 100 °C in the still head The mixture was seeded while the mixture was still boiling. The mixture was cooled down to 20 - 30 °C and the product filtered off and washed with toluene (3 times 400 ml) and dried. Yield 670 g, 93 %.
The product was purified further by a crystallisation of the base from ethanol - water. The product (670 g) was dissolved in a mixture of ethanol ( 2.66 I ) and water ( 0.7 I ) by heating to 60 °C. A solution of sodium hydroxide (121 ml , 36 %) was added. The solution was seeded while the mixture was 50 - 60 °C. The mixture was cooled down to ca. 10 °C and the product filtered off and washed with 75 % ethanol (3 times 300 ml) and dried. Yield 520 g, 79 %.
EXAMPLE 6
cis-7-Methoxy-2.2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yπethoxy]phenyl}chromane.
7-Methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-3-chromene (1 kg ) was dissolved in acetic acid (10 I) by heating to 60 °C. Palladium on carbon (10 %, 50 % wet, 100 g) was added and the mixture hydrogenated at 60 °C, 2 - 3 atmospheres hydrogen pressure for 24 hours. The mixture was cooled down to 40 - 50 CC and the catalyst filtered off. The filtrate was evaporated in vacuum to an oil. It was dissolved in 2-propanol (4 I) and sodium hydroxide was added (ca. 1.2 I, 36 %) in order to adjust the pH of the mixture to 10 - 11. The solution was seeded at 40 - 50 °C. The mixture was cooled down to ca. 5 °C and the product filtered off and washed with water (3 I) and dried at 50 °C. Yield 0.9 kg, 95 %.
EXAMPLE 7.
(- trans-7-Methoxy-2.2-dimethyl-3-phenyl-4-{4-[2-fpyrrolidin-1-yl)ethoxylphenyl}chromane hydrogen fumararate
(-)-cis-7-Methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane (-)- 0,0'-ditoluoyltartrate (15.4 g) was suspended in a mixture of toluene (77 ml), water (62 ml) and sodium carbonate (4.8 g). The mixture was stirred until all salts have dissolved. The aqueous phase was separated and extracted with another portion of toluene (20 ml). The combined organic phase was washed with water (3x20 ml). The organic phase was evaporated to an oil (9.3 g). The oil was dissolved in N-methylpyrrolidone (3.3 ml) and toluene (80 ml). Potassium tert-butoxide (1.2 g) was added and the mixture was heated to reflux while water was distilled from the mixture. The reflux was maintained for 6 hours. The reaction mixture was cooled down to room temperature, water ( 45 ml) was added and the mixture stirred until all the salt was dissolved. The aqueous phase was separated and extracted with another portion of toluene (40 ml). The organic phases were pooled washed with water (2x50 ml) and evaporated to an oil. The oil was dissolved in ethanol (16 ml) at 40 °C and mixed with a suspension of fumaric acid (4.2 g) in ethanol (31 ml) at 60 °C. The mixture was stirred. Additional ethanol (47 ml) was added and the mixture was refluxed for 3 hours. The mixture was stirred at ambient temperature overnight. The crystals were filtered off and dried.
Yield 9.9 g (85 %), m.p. 220 - 220 °C with slight decomposition. The structure of the compound was verified by 1 H-NMR and elemental analysis.

Claims

CLAIMS:
1. A process for the preparation of (-)-3,4-trans-compounds of the following formula I
wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C^alkyl, C,.6alkoxy or -0-(CH2)n-NR6R7 wherein n is an integer in the range of 1 to 6 and R6 and R7 independently are C^alkyl or R6 and R7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) which het- erocyclic group is optionally substituted with C^alkyl; and R2 and R3 are individually hydrogen or C,.6alkyl; or a salt thereof, which comprises treating a cis-racemate of a compound of formula II
wherein R1, R2 , R3 ,R4 and R5 are as defined above or a salt thereof with a chiral acid in an inert organic solvent, crystallizing the chiral acid salt of the (-)-3,4-cis enantiomer, hydrolyz- ing the optically active acid salt and rearranging the resulting (-)-3,4-cis enantiomer to the corresponding (-)-3,4-trans enantiomer of above formula I by treatment with a strong base in an aprotic solvent and optionally forming a salt thereof .
2. A process according to claim 1 , wherein R1 is hydroxy or C^alkoxy, R2 and R3 are the same and are C1-6alkyl, R4 is hydrogen and R5 is -0-(CH2)n-NR6R7 wherein n is 2 and R6 and R7 together with the N atom is a saturated or unsaturated 5- or 6- membered hetero- cyclic group containing one or two heteroatom(s) and optionally substituted with Chalky!.
3. A process according to any one of claims 1 or 2 wherein R1 is in the 7-position and R5 is in the 4-position.
4. A process according to any one of claims 1-3 wherein R1 is methoxy .
5. A process according to any one of claims 1-3 wherein R1 is hydroxy.
6. A process according to any one of claims 1-5 wherein R2 is methyl.
7. A process according to any one of claims 1-6 wherein R3 is methyl.
8. A process according to any one of claims 1-7 wherein R4 is hydrogen.
9. A process according to any one of claims 1-8 wherein R5 is pyrrolidinoethoxy.
10. A process according to claim 1 , wherein ( - ) -3R.4R- trans - 7-methoxy-2,2-dimethyl- 3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane or a salt thereof is prepared from 3,4-cis-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1 -yl)ethoxy]phenyl}chromane or a salt thereof.
11. A process according to claim 10 wherein ( - ) -3R.4R- trans - 7-methoxy-2,2- dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane is isolated as the hydrogen fumarate salt.
12. A process according to any one of the preceding claims 1-11 , wherein the reaction with the chiral acid is carried out in an C ,.β alkanol or mixtures thereof with water, tetrahydrofuran, acetone or acetonitrii.
13. A process according to any one of the preceding claims 1-12 wherein the chiral acid is (-)-di-p-toluoyltartaric acid.
14. A process according to claim 13, wherein the reaction with the (-)-di-p-toluoyltartaric acid is carried out in an C .,.6 alkanol.
15. A process according to claim 14, wherein the reaction with the (-)-di-p-toluoyltartaric acid is carried out in methanol.
16. A process according to any one of the preceding claims wherein the rearrangement of the (-)-3,4-cis enantiomer to the (-)-3,4-trans enantiomer is carried out with potassium hydroxide in dimethylsulfoxide and toluene.
17. A process according to any one of the preceding claims wherein the rearrangement of the (-)-3,4-cis enantiomer to the (-)-3,4-trans enantiomer is carried out with potassium t- butoxide in N-methylpyrrolidine and toluene.
18. A process according to any one of the preceding claims wherein the cis-racemate of formula II is obtained by hydrogenation of the corresponding 3-chromene.
19. A process according to claim 18 wherein the 3-chromene is obtained by oxidation of the corresponding (+)-3,4-cis-chromane.
20. A process according to claim 19 wherein the oxidation is carried out with chloranil and sulphur in xylene in the presence of acetic acid.
21. A process according to claim 19 wherein the oxidation is carried out with chloranil in ethylenglycol on the hydrochloride of the cis-chromane.
22. A (-)-3,4-cis enantiomer of formula III
wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C1-6alkyl, C^alkoxy or -0-(CH2)n-NR6R7 wherein n is an integer in the range of 1 to 6 and R6 and R7 independently are C^alkyl or R6 and R7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) which heterocyclic group is optionally substituted with C^alkyl; and R2 and R3 are individually hydrogen or C^alkyl; or a salt thereof.
23. The compound according to claim 22 being the (-)-di-p-toluoyltartaric acid salt having the formula
24. The compound according to any one of claims 22 or 23 wherein R1 is hydroxy or C,. 6alkoxy, R2 and R3 are the same and are Chalky!, R4 is hydrogen and R5 is -0-(CH2)n-NR6R7 wherein n is 2 and R6 and R7 together with the N atom is a saturated or unsaturated 5- or 6- membered heterocyclic group containing one or two heteroatom(s) and optionally substituted with C^alkyl.
25. The compound according to any one of claims 22-24 wherein R1 is in the 7-position and R5 is in the 4-position.
26. The compound according to any one of claims 22-25 wherein R1 is methoxy .
27. The compound according to any one of claims 22-25 wherein R1 is hydroxy.
28. The compound according to any one of claims 22-27 wherein R2 is methyl.
29. The compound according to any one of claims 22-28 wherein R3 is methyl.
30. The compound according to any one of claims 22-29 wherein R4 is hydrogen.
31. The compound according to any one of claims 22-30 wherein R5 is pyrrolidinoet- hoxy.
32. The compound according to claim 22 or 23, being 3,4-cis-7-methoxy-2,2-dimethyl-3- phenyl-4-(4-[2-(pyrrolidin-1 -yl)ethoxy]phenyl}chromane or a salt thereof.
EP97909213A 1996-10-28 1997-10-28 A process for the preparation of (-)-3,4-trans-diarylchromans Withdrawn EP0937056A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK119496 1996-10-28
DK119496 1996-10-28
DK110897 1997-09-26
DK110897 1997-09-26
PCT/DK1997/000476 WO1998018770A1 (en) 1996-10-28 1997-10-28 A process for the preparation of (-)-3,4-trans-diarylchromans

Publications (1)

Publication Number Publication Date
EP0937056A1 true EP0937056A1 (en) 1999-08-25

Family

ID=26065243

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97909213A Withdrawn EP0937056A1 (en) 1996-10-28 1997-10-28 A process for the preparation of (-)-3,4-trans-diarylchromans

Country Status (4)

Country Link
EP (1) EP0937056A1 (en)
JP (1) JP2001502703A (en)
AU (1) AU4699697A (en)
WO (1) WO1998018770A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7601855B2 (en) 2004-09-21 2009-10-13 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EA015687B1 (en) 2006-05-04 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Polymorphs
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (en) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 The salt form of organic compound
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
EA034869B1 (en) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Treatment of genotyped diabetic patients with dpp-4 inhibitors such as linagliptin
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
CN102971005A (en) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 Diabetes therapy
WO2012061413A2 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compositions and methods for the treatment of cancer
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2731947B1 (en) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (en) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Xanthine derivatives as DPP-4 inhibitors for the treatment of glomerular epithelial cell related disorders and / or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (en) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Medical use of DPP-4 inhibitors
CN116139125A (en) 2015-02-02 2023-05-23 梅制药公司 Combination therapy
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
US4447622A (en) * 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9818770A1 *

Also Published As

Publication number Publication date
JP2001502703A (en) 2001-02-27
AU4699697A (en) 1998-05-22
WO1998018770A1 (en) 1998-05-07

Similar Documents

Publication Publication Date Title
EP0937056A1 (en) A process for the preparation of (-)-3,4-trans-diarylchromans
JP2002526386A (en) Method for producing citalopram
JP3773255B2 (en) Heterocyclic compounds for treating CNS and cardiovascular diseases
WO2007016423A2 (en) Method for enantioselective hydrogenation of chromenes
AU2003287585A1 (en) Cannabinoid crystalline derivatives and process of cannabinoid purification
US5859045A (en) Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
EP1776354B1 (en) A novel process for preparation of nebivolol intermediates
EP0223744B1 (en) Flavone derivatives
US5925771A (en) Process for the preparation of (-)-3,4-trans-diarylchromans
EP1114050B1 (en) Process for the production of a naphthyridine carboxylic acid derivative ( methanesulfonate sesquihydrate )
JP5560279B2 (en) Nebivolol preparation process
Draper et al. An Efficient Process for the Synthesis of trans-2, 3-Disubstituted-2, 3-dihydro-4H-1-benzopyran-4-ones (Chroman-4-ones)
JP4461048B2 (en) Enantioselective synthesis
CN101151256B (en) Process for production of dibenzoxepin derivative
EP0906314A1 (en) Optical resolution of narwedine-type compounds
EP1073762A1 (en) Enzymatic resolvation for obtaining a (-)-3,4-trans-diarylchroman
KR20030067742A (en) Prcoess for preparing (±)trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
US6184005B1 (en) Enzymatic resolvation for obtaining a (−)-3,4-trans-diarylchroman
EP0912543B1 (en) Crystalline (-)-3r,4r-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-[4- 2-(pyrrolidin-1-yl)ethoxy]phenyl chromane, hydrogen fumarate
JPH10500421A (en) Method for producing benzopyran compound
KR100408431B1 (en) Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one or pharmaceutically acceptable salts thereof
JP3468589B2 (en) 5-aminoflavone derivative
HUT58727A (en) Process for producing new benzopyrane derivatives and pharmaceutical compositions containing them as active components
JP2002519419A (en) Process for producing (8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo [5,6] cyclohepta [1,2-B] pyridin-11-yl) -1-piperidine
EP1140910A1 (en) Process for the preparation of an acetate salt of paroxetine or paroxetine analogues

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990528

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990528;LT PAYMENT 19990528;LV PAYMENT 19990528;RO PAYMENT 19990528;SI PAYMENT 19990528

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050503